Anavex Life Sciences Corp (AVXL)

[imho]

6. Examination of subgroups is always very dicey in a statistical sense and with small groups even dicier...bordering on irrelevant at best. Focus on the super responders may be of interest but it is far less relevant than the full group.

I also welcome skepticism and appreciate your contribution. To point 6, above, why are you discounting the subgroups, if (big IF) it can be shown that the subgroups are highly correlated with dosage. It has already been determined that the drug has a positive dose response characteristic, and the company has stressed "non-optimized" dosing on every slide and PR. Of course, we do not know at this time, what the dosing effect is, but IF it can be shown that the dosing is critical to the subgroups, will you still discount the results, given the small size?

IMHO